•  home page
  •  location & contact
  • Español
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
entrechem entrechem
  • about us
    • founders
    • key personnel
    • funding
    • strategy
  • pipeline
    • pipeline chart
    • EC-8042
    • EC-70124
  • technology
    • natural products
    • synthetic biology
    • biocatalysis
      • DA · enantiomerically pure chiral diamines
      • AA · enantiomerically pure chiral amino alcohols
      • IA · enantiomerically pure chiral amino indanes
  • collaborations
    • scientific collaborators
    • collaborative projects
  • publications
    • EC-8042
    • EC-70124
    • biocatalysis
    • synthetic biology
  • news
Apr 28

AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL

The pharmaceutical company AI-Therapeutics (Guilford, CT, USA) has acquired the preclinical drug candidates EC-8042 and EC-70124 in the course of the insolvency proceedings EntreChem was experiencing since February of last year. The insolvency event left unfinished the development of both drugs, that were on the verge of facing the first... read more →
  • 28 April, 2022
  • Agreements, Financing
Jun 24

EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor

Rhabdoid tumor is a pediatric cancer characterized by the biallelic inactivation of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex. SMARCB1 inactivation leads to SWI/SNF redistribution to favor a proliferative dedifferentiated cellular state. Although this deletion is the known oncogenic driver, SWI/SNF therapeutic targeting remains a challenge. Mithralog... read more →
  • 24 June, 2021
  • Publications
May 30

EntreChem participates in the ERA-Co-Biotech project «MISSION»

EntreChem, 2 European Universities and Novartis to cooperate in the project "MISSION: Streamlined Streptomyces cell factories for industrial production of valuable natural products." The European Commission has awarded €1.8M to the ERA-CoBiotech project "MISSION - Streamlined Streptomyces cell factories for industrial production of valuable natural products." The project belongs... read more →
  • 30 May, 2018
  • Projects
Jan 17

EC-70124 acts as dual FLT3 PIM inhibitor and exerts potent activity in acute myeloid leukemia

Acute Myeloid Leukemia (AML) is the most common myeloid malignancy in adults, and Internal Tandem Duplication (ITD) or kinase domain mutation of FLT3 represent the most frequent genetic alteration, accounting for 30% of cases associated with poor disease outcome. On the other hand, PIM kinases play an important role... read more →
  • 17 January, 2018
  • Publications
May 02

New Oncotarget publication: EntreChem’s mithralog EC-8042 targets sarcoma cancer stem cells by inhibiting SP1 transcription factor

Sarcoma models derived from human mesenchymal stromal/stem cells (hMSCs) are used to understand better the initiation of sarcomagenesis, not amenable to analysis in patient samples or cell lines. This study shows that the signaling mediated by SP1 is altered in transformed hMSCs able to initiate sarcomas in vivo. The inhibition... read more →
  • 2 May, 2016
  • Publications
Apr 04

EntreChem’s mithralog EC-8042 promising activity for Ewing sarcoma, published in Clinical Cancer Research

The fusion protein EWS-FLI1 is a constitutively activated transcription factor responsible for the oncogenic phenotype of Ewing sarcoma (EWS). Mithramycin is a potent inhibitor of EWS-FLI1, but its toxicity makes it desirable to identify more potent and/or a less toxic analogs to inhibit EWS-FLI1 at clinically achievable concentrations. EntreChem's mithralog... read more →
  • 4 April, 2016
  • Publications
Mar 10

EntreChem’s orally active EC-70124 reverts tumorigenic and stem cell properties in prostate cancer

Cancer stem cells (CSCs) contribute to disease progression and treatment failure in prostate cancer because of their intrinsic resistance to current therapies. The transcription factors NF-κB and STAT3 are frequently activated in advanced prostate cancer and sustain expansion of prostate CSCs. EC-70124, is a potent dual inhibitor of the NF-kB... read more →
  • 10 March, 2016
  • Publications
Dec 21

New EntreChem publication in Oncotarget describing activity of EC-70124 in colorectal cancer

Activated kinases were identified by using phosphokinase arrays with human colorectal tumor samples, including the Epidermal Growth Factor Receptor (EGFR), components of the PI3K/mTOR pathway (AKT and S6), and SRC, among others. EC-7012, a kinase inhibitor, shows high in vitro antiproliferative activity as well as cell migration inhibition. Major effects... read more →
  • 21 December, 2015
  • Publications
Oct 20

EntreChem publishes two studies in Oncotarget regarding activity of EC-70124 and EC-8042 in triple negative breast cancer

EC-70124, a kinase inhibitor, shows in vitro and in vivo antiproliferative effects mediated by simultaneous inhibition of the PI3K/mTOR y JAK/STAT signaling pathways and also DNA damage induction, causing cell cycle arrest on G2/M. The combination with docetaxel is synergistic, both in vitro and in vivo, offering opportunities for combination... read more →
  • 20 October, 2015
  • Publications
May 11

EntreChem participates in the ERA-IB project «NeBrasCa – Next Generation Immunosuppressants: Brasilicardin synthesized by Nocardia spp»

EntreChem and three Universities from three European countries to cooperate in the project. The European Commission has awarded €1 million to the ERA-IB project "NeBrasCa - Next Generation Immunosuppressants: Brasilicardin synthesized by Nocardia spp." The project belongs to the European Research Agency - Industrial Biotechnology program (ERA-IB), and it aims... read more →
  • 11 May, 2015
  • Projects
  • 1
  • 2
  • 3
  • 4

Next Page »

latest news

  • AI-Therapeutics acquires the preclinical drugs EC-8042 and EC-70124 from EntreChem SL
  • EC-8042 targets SWI/SNF complex vulnerabilities and induces epigenetic reprogramming and permanent cures in rhabdoid tumor
  • EntreChem participates in the ERA-Co-Biotech project «MISSION»

categories

  • Agreements
  • Financing
  • Projects
  • Publications
  • Research
  • Other

archive

EntreChem, S.L.

Vivero Ciencias de la Salud,
c/ Colegio Santo Domingo de Guzmán s/n,
33011 Oviedo, Spain

info@entrechem.com

pipeline  /  chart
· EC-8042
· EC-70124

scientific collaborators
collaborative projects

  • about us
  • technology
  • publications
  • news
Copyright © 2023 EntreChem, S.L. All rights reserved.
  • privacy policy
  • usage policy
  • cookies policy

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

Privacy Overview
entrechem

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Cookie Policy

You can consult our cookies policy for more information.